Share

Delighted to announce that TRUEinvivo® has recently been awarded the medical CE Mark for our fast automated DOSEmapper Reader. This Class IIb medical device reads 300 micro silica bead thermoluminescent dosimeters (TLDs) in an hour without any manual interaction. Strings of characterised and calibrated bead TLDs are used to make DOSEmapper devices to enable clinicians to measure directly the actual radiotherapy doses (which are dozens of micro doses) that reach a target tumour. From the very first patient session, clinicians can compare those actual doses with the patient treatment plan and can make corrections for any system inaccuracies.

This facility gives clinicians early feedback and confidence about the overall treatment, it reduces side effects and their medical costs or re-treatment, and it gives patients a better experience and quality of life.
Related Posts
Revolutionary DOSEmapper™ reader produces glow curve graph, offering rapid measurement compared to traditional TLD readers.
Innovate UK showcases TRUEinvivo® founder for Women in Innovation award, spotlighting Dr. Shakardokht Jafari's success.
This order is for a number of DOSEmapper™ devices and for our DOSEmapper™ Bead Reading Service.
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021